Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP-9722 in advanced solid tumors
NCT01311713Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CEP-9722 in solid tumor, sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2011; status: terminated.
02
Drugs
CEP-9722
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01311713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01311713.